BioScrip initiated at Canaccord

BioScrip initiated with a Buy at Canaccord. Canaccord analyst Richard Close initiated BioScrip with a Buy rating and $5 price target. In a research note to investors, Close says that he expects BioScrip to increasingly gain investor attention as the turnaround initiated in 2H16 continues. For the first time in its history, Close believes BioScrip is on a clear path to double-digit EBITDA margin in 2019 and says shares can continue to move higher as the turnaround nears completion, management initiates on new growth and margin expansion strategies, and the company’s high leverage and debt structure is rightsized in the coming year.

https://thefly.com/landingPageNews.php?id=2835829